Diagnostic procedures of pleural malignant mesothelioma: Our experience

Journal of B.U.ON.

Volumn 9, Issue 4, 2004, Pages 423-426

  Stojsic, Jelena ^a,c   Spasic, Z ^a   Velinovic, M ^a   Adzic, T ^a   Maric, D ^a   Todorovic, V ^b   Drndarevic, N ^b  

^a Inst for Lung Diseases Tuberculosis   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c NONE   (Serbia)

Author keywords

Adenocarcinoma; Immunohistochemistry; Lung; Malignant mesothelioma; Pleura

Indexed keywords

CALRETININ; CYTOKERATIN 5; CYTOKERATIN 6; MONOCLONAL ANTIBODY; SURFACTANT PROTEIN A; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EPITHELIOID CELL; EXPERIENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG ADENOCARCINOMA; MALIGNANT MESOTHELIOMA; MEDICAL DECISION MAKING; PLEURA BIOPSY; PLEURA MESOTHELIOMA; SENSITIVITY ANALYSIS; SPINDLE CELL SARCOMA; TREATMENT PLANNING;

EID: 14044272994     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. Mesothelial tumours. World Health Organisation International Histological Classification of Tumours (3rd edn). Berlin, Springer, 1999, pp 51-54.
2. Taylor CR, Cote RJ (eds). Immunomicroscopy: A diagnostic tool for the surgical pathologist (2nd edn). Philadelphia, WB Saunders, 1994, pp 12-32.
3. Dabbs DJ (ed). Diagnostic immunohistochemistry; pleural neoplasms. Philadelphia, Churchill Livingstone, 2002, pp 285-305.
4. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002; 55: 662-668.
5. Oates J, Edwards C. HBME-1, MOC-31, WT1, and calretinin: as assessement of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-347.
6. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and trombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997; 21: 1399-1408.
7. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11: 929-933.
8. Doglioni C, Dei Tos AP, Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037-1046.
9. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22: 1215-1221.
10. Han AC, Filstein MR, Hunt JV et al. N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: immunocytochemical study. Cancer 1999; 87: 83-86.
11. Han AC, Peralta-Soler A, Knudsen KA et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin- embedded tissue. Hum Pathol 1997; 28: 641-645.
12. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985; 9: 360-365.
13. Jasani B, Edwards RE, Thomas ND et al. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch 1985; 406: 441-448.
14. Ordóñez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinoma. Adv Anat Pathol 2000; 7: 123-127.
15. Marson VJ, Mazieris J, Groussard O et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumors: correlation with histological type and grade. Histopathology 2004; 45: 125-134.
16. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 2004; 57: 383-387.
17. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma from adenocarcinoma. Am J Surg Pathol 1989; 13: 276-291.
18. Brockstedt U, Gulyas M, Dobra K et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000; 114: 203-209.
19. Brown RW, Clark GM, Tandon AK et al. Multiple marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from adenocarcinoma. Hum Pathol 1993; 24: 347-354.